$WVE News
Last published 11h ago
- 11h agoWVEWave Life Sciences to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswireCAMBRIDGE, Mass., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conferen ...
- 1w agoWVEWave Life Sciences Research Day - WAVE LIFE SCIENCES INCEarnings Call TranscriptsHello, and welcome to WAVES 2026 Research Day. We ask that you please hold all questions until the completion of the formal remarks, at which time you'll be given instructions for the question and answer session. Also, a
- 2w agoWVEThird Quarter 2026 Earnings Call - WAVE LIFE SCIENCES INCEarnings Call TranscriptsHello and welcome to Wave Life Sciences third quarter 2026 earnings call. We ask that you please hold all questions until the completion of the formal remarks at which time you'll be given instructions for the question a
- 2w agoWVEThird Quarter 2026 Earnings Call - WAVE LIFE SCIENCES INCEarnings Call TranscriptsHello and welcome to Wave Life Sciences third quarter 2026 earnings call. We ask that you please hold all questions until the completion of the formal remarks at which time you'll be given instructions for the question a
- 2w agoWVEThird Quarter 2026 Earnings Call - WAVE LIFE SCIENCES INCEarnings Call TranscriptsHello and welcome to Wave Life Sciences third quarter 2026 earnings call. We ask that you please hold all questions until the completion of the formal remarks at which time you'll be given instructions for the question a
- 2w agoWVEWave Life Sciences, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoWVEWave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswirePlanning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers Advancing WVE-007 (INHBE siRNA) across treatment
- 3w agoWVERNA Medicines: Next-Generation RNA Therapeutics - WAVE LIFE SCIENCES INCEarnings Call TranscriptsI want to welcome you to this session, RNA Medicines, Next Generation, RNA Therapeutics. My name is Kane Akai. I'm the director of research and one of the senior biotech analysts at Chardon. And I want welcome our speake
- 3w agoWVEWave Life Sciences Third Quarter 2026 Financial Results Scheduled for October 27, 2026GlobeNewswireCAMBRIDGE, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 3w agoWVEWave Life Sciences to Host Virtual Research Day on Wednesday, November 4, 2026GlobeNewswireCAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 4w agoWVEWave Life Sciences to Present at Chardan’s 10th Annual Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 2mo agoWVEWave Life Sciences to Present at Cantor 2026 Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 3mo agoWVECG 46TH ANNUAL GROWTH CONFERENCE - WAVE LIFE SCIENCES INCEarnings Call TranscriptsAll right, good morning still. Yes, everyone, thank you for joining us. My name is Whitney Egyem. I'm one of the biotech analysts here at Canaccord, and I'm pleased to be chatting now with Wave Life Sciences and Presiden
- 3mo agoWVECG 46TH ANNUAL GROWTH CONFERENCE - WAVE LIFE SCIENCES INCEarnings Call TranscriptsAll right, good morning still. Yes, everyone, thank you for joining us. My name is Whitney Egyem. I'm one of the biotech analysts here at Canaccord, and I'm pleased to be chatting now with Wave Life Sciences and Presiden
- 3mo agoWVE2026 SMID CAP EXECUTIVE INSIGHTS EVENT (VIRTUAL) - WAVE LIFE SCIENCES INCEarnings Call TranscriptsHi, everyone. Just wanted to come on to welcome everyone to this session of our SMITCAP Executive Insights virtual event. So I'm Jill Hall, Head of Small and Mid-Cap Strategy here at Global Research. So we're very happy
- 3mo agoWVEWave Life Sciences Announces Completion of Redomiciliation to DelawareGlobeNewswireCAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences, Inc. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health
- 3mo agoWVEWave Life Sciences Announces Expected Completion Date for Redomiciliation to DelawareGlobeNewswireCAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to
- 3mo agoWVEWave Life Sciences to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 3mo agoWVESecond Quarter 2026 Earnings Call - WAVE LIFE SCIENCES INCEarnings Call Transcripts🎵 Outro Music 🎵 Thank you. Oh, sorry. Testing 1, 2, 3, 4, 5. Audio test for the live stream. I completely spaced out with that one. Sorry about that. Thank you. Thank you. Thank you. Thank you. We'll be right back. Tha
- 3mo agoWVEWave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireDosing underway in Phase 2a multidose portion of the INLIGHTTM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m2) and comorbidities; trial will also inform WVE-007's potential in
- 3mo agoWVEWave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026GlobeNewswireCAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 4mo agoWVEWave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for RedomiciliationGlobeNewswireCAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to
- 4mo agoWVEWave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic DiseasesGlobeNewswireIn Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing Phase 2a portion in
- 5mo agoWVEGoldman Sachs 47th Annual Global Healthcare Conference - WAVE LIFE SCIENCES INCEarnings Call TranscriptsWelcome. Thanks, Rob. Welcome to the inaugural session of the 47th Annual Goldman Sachs Healthcare Research Conference. Pleased to be joined by Wave Life Sciences and Paul. So, first, Paul, for those in the audience and
- 5mo agoWVEWave Life Sciences to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 5mo agoWVEWave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1PR NewswireAlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Wave Life Sciences as an inaugural...
- 5mo agoWVEWVE-006: RNA Editing for AATD Interim RestorAATion-2 Clinical Data - WAVE LIFE SCIENCES INCEarnings Call TranscriptsThank you so much for joining us. Thank you. Thank you. Thank you. I'll see you next time. We'll be right back. Thank you. Thanks for watching! testing one two three four five five four three two one and i did it without
- 5mo agoWVEWave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly DosingGlobeNewswireData reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing On
- 6mo agoWVEWave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today
- 6mo agoWVEWave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireWith recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track
- 6mo agoWVEWave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026GlobeNewswireCAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 6mo agoWVEWave Life Sciences Announces Hearing on Proposed Redomiciliation to the United StatesGlobeNewswireCAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to
- 7mo agoWVEWave Life Sciences Announces Proposed Redomiciliation to the United StatesGlobeNewswireCAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 7mo agoWVEWave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007GlobeNewswireAt 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p<0.05) and total fat (-5%), stabilization of lean mass
- 8mo agoWVEDNLIMRNAGMTX+6FDA reversals leave investors worrying about the fates of other experimental drugsCNBCInvestors are scrutinizing the prospects for some drugs in the pipeline following a string of recent rejections from the U.S. Food and Drug Administration.
- 8mo agoWVEWave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International ConferenceGlobeNewswireData from the RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing), including new data from the 400 mg multidose cohort and 600 mg single dose cohort, will now be presented at the ATS conference CAMBRIDGE,
- 8mo agoWVEWave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswireOn track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while preserving muscle
- 8mo agoWVEWave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewswireCAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 8mo agoWVEWave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026GlobeNewswireCAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will
- 9mo agoWVEWave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin DeficiencyGlobeNewswireWVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address
- 10mo agoWVEWave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing PortfolioGlobeNewswireWave expects to initiate a Phase 2a multidose portion of WVE-007 INLIGHT clinical trial in individuals living with obesity with higher BMI and comorbidities in 1H 2026, and initiate new trials of WVE-007 as an add-on to
- 10mo agoWVEWave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 11mo agoWVEWave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewswireCAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health
- 11mo agoWVEWave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded WarrantsGlobeNewswireCAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health
- 11mo agoKBLBPAVSTWGWVETurnarounds and 18,000% GrowthGlobeNewswireDENVER, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Markets opened the week with a burst of small-cap energy as several niche innovators, spanning luxury foods, next-gen biomaterials, and RNA therapeutics, delivered updates that
- 11mo agoWVEWave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle LossGlobeNewswireFollowing a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat
- 11mo agoWVEWave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025GlobeNewswireCAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will
- 1y agoWVEWave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business UpdateGlobeNewswireWVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led
- 1y agoWVEWave Life Sciences to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health,
- 1y agoWVEWave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025GlobeNewswirePresentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving muscle mass with once or